EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

被引：0

作者：

Reardon, David ^{[1
]}

Idbaih, Ahmed ^{[2
]}

Vieito, Maria ^{[3
]}

Ghiringhelli, Francois ^{[4
]}

Stradella, Agostina ^{[5
]}

Tabatabai, Ghazaleh ^{[6
,7
]}

Burger, Michael C. ^{[8
]}

Mildenberger, Iris ^{[9
]}

Herrlinger, Ulrich ^{[10
,11
]}

Wen, Patrick ^{[12
]}

Touat, Mehdi ^{[13
]}

Wick, Antje ^{[14
]}

Gonzalez, Macarena ^{[3
]}

Hervieu, Alice ^{[4
]}

GilMartin, Marta

Renovanz, Mirjam ^{[15
]}

Gouttefangeas, Cecile ^{[16
]}

Maia, Ana ^{[16
]}

Bonny, Christophe ^{[17
]}

Paillarse, Jean-Michel ^{[17
]}

Chene, Laurent ^{[17
]}

Fagerberg, Jan ^{[17
]}

Wick, Wolfgang ^{[14
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA

[2] Sorbonne Univ, Hop Univ La Pitie Salpetriere, AP HP, ICM, Paris, France

[3] Hosp Univ Vall dHebron, Barcelona, Spain

[4] Ctr Georges Francois Leclerc, Dijon, France

[5] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[6] Univ Hosp Tubingen, Comprehens Canc Ctr, Ctr Neurooncol, Dept Neurol & Interdisciplinary Neurooncol, Tubingen, Germany

[7] Eberhard Karls Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany

[8] Goethe Univ Hosp, Dr Senckenberg Inst Neurooncol, Frankfurt, Germany

[9] Med Fak Mannheim, Mannheim, Germany

[10] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol, Bonn, Germany

[11] Univ Hosp Bonn, Ctr Integrated Oncol, Bonn, Germany

[12] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[13] Hop Univ La Pitie Salpetriere, Paris, France

[14] Univ Klinikum Heidelberg, Heidelberg, Baden Wurttembe, Germany

[15] Univ Hosp Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Interdisciplinary Neurooncol, Tubingen, Germany

[16] Eberhard Karls Univ Tubingen, Dept Immunol, Tubingen, Germany

[17] Enterome, Paris, France

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-25

引用

页数：1

共 37 条

[1] EO2401 (E) peptide immunotherapy plus nivolumab (N) plus /- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE
Wick, Wolfgang
Idbaih, Ahmed
Vieito, Maria
Ghiringhelli, Francois
Stradella, Agostina
Tabatabai, Ghazaleh
Burger, Michael C.
Mildenberger, Iris
Herrlinger, Ulrich
Wen, Patrick Y.
Touat, Mehdi
Wick, Antje
Gonzalez, Macarena
Hervieu, Alice
Gil-Martin, Marta
Renovanz, Mirjam
Maia, Ana
Bonny, Christophe
Fagerberg, Jan
Reardon, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] EO2401 MICROBIOME DERIVED THERAPEUTIC VACCINE plus NIVOLUMAB, WITH/WITHOUT STANDARD CONTINUOUS, OR LOW-DOSE SYMPTOM DIRECTED, BEVACIZUMAB, IN RECURRENT GLIOBLASTOMA: PHASE 1-2 EOGBM1-18/ROSALIE STUDY
Reardon, David
Idbaih, Ahmed
Vieito, Maria
Tabatabai, Ghazaleh
Stradella, Agostina
Ghiringhelli, Francois
Burger, Michael
Mildenberger, Iris
Herrlinger, Ulrich
Gonzalez, Macarena
GilMartin, Marta
Renovanz, Mirjam
Touat, Mehdi
Wen, Patrick
Wick, Antje
Gouttefangeas, Cecile
Maia, Ana
Bonny, Chistophe
Fagerberg, Jan
Wick, Wolfgang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A673 - A673
[3] STRONG IMMUNE RESPONSE TO THERAPEUTIC VACCINATION WITH EO2401 MICROBIOME DERIVED THERAPEUTIC VACCINE plus NIVOLUMAB: INTERIM REPORT OF THE EOGBM1-18/ROSALIE STUDY
Maia, Ana
Toussaint, Helene
Magalhaes, Joao Gamelas
Reardon, David
Idbaih, Ahmed
Vieito, Maria
Tabatabai, Ghazaleh
Stradella, Agostina
Ghiringhelli, Francois
Burger, Michael C.
Mildenberger, Iris
Herrlinger, Ulrich
Gonzalez, Macarena
Hervieu, Alice
GilMartin, Marta
Renovanz, Mirjam
Touat, Mehdi
Wen, Patrick Y.
Wick, Antje
Chene, Laurent
Gouttefangeas, Cecile
Bonny, Christophe
Fagerberg, Jan
Wick, Wolfgang
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A672 - A672
[4] THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)
Reardon, David A.
Idbaih, Ahmed
Vieito, Maria
Tabatabai, Ghazaleh
Stradella, Agostina
Ghiringhelli, Francois
Burger, Michael C.
Mildenberger, Iris
Gonzalez, Macarena
Hervieu, Alice
Martin, Marta Gil
Renovanz, Mirjam
Touat, Mehdi
Wen, Patrick Y.
Wick, Antje
Gouttefangeas, Cecile
Maia, Ana
Bonny, Christophe
Fagerberg, Jan
Wick, Wolfgang
NEURO-ONCOLOGY, 2022, 24 : 63 - 63
[5] EO2401 (E) peptide immunotherapy plus nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
Baudin, E.
Grisanti, S.
van Oordt, C. W. Menke-van der Houven
Haak, H.
Castillon, J. Capdevila
Fassnacht, M.
Subbiah, V.
Jimenez, C.
de la Fouchardiere, C.
Yachnin, J.
Granberg, D.
Kroiss, M.
Daugaard, K. G.
Cosentini, D.
Lamartina, L.
Paillarse, J-M.
Aubergeon, L.
Fagerberg, J.
Chene, L.
Berruti, A.
ANNALS OF ONCOLOGY, 2023, 34 : S498 - S499
[6] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Ahluwalia, Manmeet
Peereboom, David
Schilero, Cathy
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[7] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
Ahluwalia, Manmeet
Fallah, Jaleh
Peereboom, David
Schilero, Cathy
Ali, Assad
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2019, 21 : 220 - 220
[8] ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL
Nassiri, Farshad
Patil, Vikas
Yefet, Leeor
Singh, Olivia
Liu, Jeff
Dang, Rachel
Yamaguchi, Takafumi
Daras, Mariza
Cloughesy, Timothy
Colman, Howard
Kumthekar, Priya
Chen, Clark
Aiken, Robert
Groves, Morris
Ong, Shirley
Ramakrishna, Rohan
Vogelbaum, Michael A.
Khagi, Simon
Kaley, Thomas
Melear, Jason
Peereboom, David
Rodriguez, Analiz
Yankelevich, Maxim
Nair, Suresh
Puduvalli, Vinay
Aldape, Kenneth
Gao, Andrew
Lopez-Janeiro, Alvaro
de Andrea, Carlos
Alonso, Marta
Boutros, Paul
Robbins, Joan
Mason, Warren
Sonaben, Adam
Stupp, Roger
Fueyo-Margareto, Juan
Gomez-Manzano, Candelaria
Lang, Frederick
Zadeh, Gelareh
NEURO-ONCOLOGY, 2023, 25
[9] Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nassiri, Farshad
Patil, Vikas
Yefet, Leeor S.
Singh, Olivia
Liu, Jeff
Dang, Rachel M. A.
Yamaguchi, Takafumi N.
Daras, Mariza
Cloughesy, Timothy F.
Colman, Howard
Kumthekar, Priya U.
Chen, Clark C.
Aiken, Robert
Groves, Morris D.
Ong, Shirley S.
Ramakrishna, Rohan
Vogelbaum, Michael A.
Khagi, Simon
Kaley, Thomas
Melear, Jason M.
Peereboom, David M.
Rodriguez, Analiz
Yankelevich, Maxim
Nair, Suresh G.
Puduvalli, Vinay K.
Aldape, Kenneth
Gao, Andrew
Lopez-Janeiro, Alvaro
de Andrea, Carlos E.
Alonso, Marta M.
Boutros, Paul
Robbins, Joan
Mason, Warren P.
Sonabend, Adam M.
Stupp, Roger
Fueyo, Juan
Gomez-Manzano, Candelaria
Lang, Frederick F.
Zadeh, Gelareh
NATURE MEDICINE, 2023, 29 (06) : 1370 - +
[10] Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri
Vikas Patil
Leeor S. Yefet
Olivia Singh
Jeff Liu
Rachel M. A. Dang
Takafumi N. Yamaguchi
Mariza Daras
Timothy F. Cloughesy
Howard Colman
Priya U. Kumthekar
Clark C. Chen
Robert Aiken
Morris D. Groves
Shirley S. Ong
Rohan Ramakrishna
Michael A. Vogelbaum
Simon Khagi
Thomas Kaley
Jason M. Melear
David M. Peereboom
Analiz Rodriguez
Maxim Yankelevich
Suresh G. Nair
Vinay K. Puduvalli
Kenneth Aldape
Andrew Gao
Álvaro López-Janeiro
Carlos E. de Andrea
Marta M. Alonso
Paul Boutros
Joan Robbins
Warren P. Mason
Adam M. Sonabend
Roger Stupp
Juan Fueyo
Candelaria Gomez-Manzano
Frederick F. Lang
Gelareh Zadeh
Nature Medicine, 2023, 29 : 1370 - 1378

← 1 2 3 4 →